Biogen Idec EVP Sells $494,862 in Stock (BIIB)
Biogen Idec (NASDAQ:BIIB) EVP Kenneth Dipietro sold 1,655 shares of the company’s stock on the open market in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $299.01, for a total transaction of $494,861.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
BIIB has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Biogen Idec from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday. They now have a $375.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of Biogen Idec from $310.00 to $360.00 in a research note to investors on Thursday, January 30th. They now have a “buy” rating on the stock. Nine investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $301.00.
Biogen Idec (NASDAQ:BIIB) traded down 2.68% during mid-day trading on Wednesday, hitting $299.93. 1,888,103 shares of the company’s stock traded hands. Biogen Idec has a 52-week low of $158.75 and a 52-week high of $321.25. The stock has a 50-day moving average of $291.9 and a 200-day moving average of $252.6. The company has a market cap of $70.868 billion and a price-to-earnings ratio of 39.46.
Biogen Idec (NASDAQ:BIIB) last announced its earnings results on Wednesday, January 29th. The company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.07. The company had revenue of $2.00 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. On average, analysts predict that Biogen Idec will post $11.33 earnings per share for the current fiscal year.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.